REUTERS                                                                                              Dec. 19, 2014

GENEVA –  Trials of GlaxoSmithKline's experimental Ebola vaccine are likely to move to a second phase in February, later than previously suggested, after a meeting of national regulators said they needed more information.

The World Health Organization, which hosted a meeting of national regulatory authorities and ethics committees earlier this week, said they had thoroughly discussed all aspects of the proposed trials at the two-day meeting.

"Reviewing countries requested additional documentation from the manufacturer of the vaccine, GlaxoSmithKline, before authorization of the trials," the WHO said in a statement.

Countries where the trials are planned -- Cameroon, Ghana, Mali, Nigeria and Senegal -- should receive and review the additional information by the end of January.

"If these steps are completed to the satisfaction of the national authorities, Phase II trials are likely to begin in February," the statement said.

The GSK vaccine is already undergoing Phase I trials, to check its safety in humans, in Switzerland, Britain, Mali and the United States, and is one of the two leading candidate vaccines for Ebola already undergoing tests.

NBC NEWS by Maggie Fox                                                                                                      Dec. 19, 2014

German doctors think they have another possible drug to add to the Ebola treatment pipeline. It's one already shown to be safe and in trials to treat heart attack victims.

The drug, called FX06, is made using a natural human blood-clotting protein called fibrin. The hope is it can help reduce the leaking of blood vessels that can seriously threaten people with advanced Ebola infections.

The team at Frankfurt University Hospital say it may have helped save a Ugandan doctor they treated, although they note it failed to save a second patient.

Nonetheless, it should be tested, they wrote in the Lancet medical journal.

"Even though the patient was critically ill, we were able to support him long enough for his body to start antibody production and for the virus to be cleared by his body's defenses," said Dr. Timo Wolf, who helped lead the research team. "FX06 could potentially be a valuable agent in contribution to supportive therapy."

Read complete story.

CENTER FOR INFECTIOUS DISEASE RESEARCH AND POLICY   by Lisa Schnirring                                   Dec. 17, 2014
            
Sierra Leone's rising Ebola activity seems to be slowing as a major effort to knock down the disease gets under way; disease incidence is still fluctuating in Guinea and cases continue to decline in Liberia, the World Health Organization (WHO) said today in its latest update.

The global Ebola total as of Dec 14 has reached 18,603 cases, along with 6,915 reported deaths, the WHO said. Numbers reflect an increase of 661 infections and 527 deaths since the last report Dec 10. Sierra Leone, with 327 new cases, accounted for more than half the increase, while Guinea reported 76 more. Liberia reported eight new confirmed cases, but its total includes only those reported as of Dec 9.

The WHO said progress is occurring in all three of the hardest-hit countries toward the United Nations' goal of isolating and treating 100% of Ebola patients and safely burying 100% of those who die from the disease by Jan 1. All countries now have enough treatment beds, though some are unevenly distributed, resulting in shortages in some areas, the WHO said.

ETHIOSPORTS  by Raphael Simon                                                                 Dec. 18, 2014    
Freetown, Sierra Leone: - The Africa Union has aided Sierra Leone with 101 Ethiopian Medical personnel in the fight against Ebola. The medical team comprised Doctors, Nurses, Pharmacists, Epidemiologists, Public Health Officers, and Information and Communication Specialists...